Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRCX014 Safety and PK in Glioblastoma
NCT03687034Phase 1Unknown
- Sponsor
- Diverse Biotech
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of cannabidiol in glioblastoma (GBM), sponsored by Diverse Biotech. Primary endpoint: Number of participants with treatment-related adverse events at 1 year. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03687034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687034.